Page last updated: 2024-11-03

raloxifene and Leiomyoma

raloxifene has been researched along with Leiomyoma in 1 studies

raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.

Leiomyoma: A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hummel, CW1
Geiser, AG1
Bryant, HU1
Cohen, IR1
Dally, RD1
Fong, KC1
Frank, SA1
Hinklin, R1
Jones, SA1
Lewis, G1
McCann, DJ1
Rudmann, DG1
Shepherd, TA1
Tian, H1
Wallace, OB1
Wang, M1
Wang, Y1
Dodge, JA1

Other Studies

1 other study available for raloxifene and Leiomyoma

ArticleYear
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
    Journal of medicinal chemistry, 2005, Nov-03, Volume: 48, Issue:22

    Topics: Animals; Binding Sites; Biological Availability; Cell Line; Cell Proliferation; Estradiol; Estrogen

2005